Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

scPharmaceuticals Inc. (SCPH) — this company's answers

NO on the Q3 2023 call 2023-11-08 B
The model's full reasoning — Q3 2023 call → NO我们根据指令分析。需要识别一个明确的、公司特定的疑虑,并且当前期间的实际运营证据是否明显反驳该疑虑。 从电话会议中,我们看到公司正在推出FUROSCIX,一个新产品。分析师的问题集中在处方量、每处方剂量、IDN合同、销售代表增加等。管理层讨论了收入增长、处方增长、新合同等。 疑虑可能是什么?可能是关于产品采用率、处方转化率、患者获取、支付方覆盖等。但电话会议中,管理层似乎很乐观,分析师的问题也多是询问细节,没有明显的负面疑虑。不过,有一个点:管理层提到“fill rate”为55%,且提到取消原因包括高自付费用。但整体上,公司处于早期商业化阶段,亏损扩大(净亏损从1020万增至1560万),但收入增长。分析师没有直接质疑公司能否盈利,但可能隐含。 再读:管理层说“我们仍然非常满意FUROSCIX的推出轨迹”,并提到新增销售代表、IDN合同等。分析师的问题如“处方量增加但每处方剂量也增加”等,没有明显疑虑。 也许疑虑是“公司能否实现盈利”或“产品需求是否可持续”?但电话会议中,管理层没有直接回应这种疑虑,而是展示增长数据。然而,指令要求“standing knock”在电话会议中可见,即分析师或管理层提及的疑虑。例如,分析师问“处方量增加但每处方剂量也增加”可能暗示对剂量可持续性的担忧?但这不是明确的疑虑。 再考虑:管理层提到“GTN为21%”,并说“我们预计会随着合同增加而上升”,这可能暗示对利润率担忧。但这不是主要。 或许疑虑是“公司依赖单一产品”或“商业化初期的不确定性”。但电话会议中,管理层积极回应。 仔细看,分析师Nik Gasic问“IDN直接购买协议的规模和频率”,这可能是对收入来源的担忧。但管理层回答积极。 另一个可能:管理层提到“我们无法看到IDN的处方量”,这可能引起对数据透明度的担忧,但未明确。 指令要求“clearly weighing on how this company is perceived”,即一个明显的疑虑。在电话会议中,没有分析师直接说“我们担心亏损”或“我们担心需求”。但管理层在开场白中说“我们相信专家们正在迅速获得处方信心”,这暗示可能有人怀疑。 也许疑虑是“产品采用速度慢”或“处方转化率低”?但管理层给出了具体数字:处方从631增至1119,填充率从52%增至55%,这些是积极证据。 再读:管理层说“我们预计填充率将继续提高”,这暗示当前填充率可能被视为低。但分析师没有直接质疑。 或许疑虑是“公司现金消耗”或“融资需求”?但管理层没有提及融资,现金从118.4降至90.2,但这是正常。 我认为没有明显的、公司特定的、预先存在的疑虑在电话会议中被明确提及。分析师的问题都是中性的,管理层也自信。因此,答案应为NO。 但指令要求“the doubt must be specific to this company's situation”,并且“read as something that predates this quarter”。在电话会议中,没有这样的表述。管理层提到“我们之前说过要达到75%的患者有固定共付”,这可能是对支付方覆盖的担忧,但那是目标。 或许疑虑是“公司能否获得支付方覆盖”?但管理层宣布了新的合同,这反驳了。 总之,没有明显的疑虑。因此,答案NO。

← Back to the full SCPH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.